泛素
重编程
富维斯特朗
泛素连接酶
泛素蛋白连接酶类
分子肿瘤学
医学
生物信息学
癌症研究
三氧化二砷
雌激素受体
癌症
计算生物学
生物
平方毫米
神经科学
融合蛋白
药理学
胶质母细胞瘤
克里唑蒂尼
作者
Gina Gotthardt,Jan Keiten‐Schmitz,Stefan P Müller
标识
DOI:10.1016/j.tips.2025.09.002
摘要
Drugs that reprogram the cellular ubiquitin-proteasome system for removal of disease-causing proteins hold great promise as a new type of pharmacology. Small ubiquitin-related modifier (SUMO)-targeted ubiquitin ligases (StUbLs) are E3 ubiquitin ligases that mediate ubiquitylation of proteins primed by modification with SUMO. The antineoplastic drugs arsenic trioxide and fulvestrant stand out as examples for leveraging a SUMOylation-ubiquitylation cascade to inactivate the oncogenic fusion proteins PML-RARα and estrogen receptor α, respectively. However, approaches harnessing the StUbL system for targeting a broader spectrum of disease-relevant proteins are missing. Recent proof-of-concept studies indicate that proximity-inducing modalities can recruit aggregation-prone proteins to the StUbL machinery, potentially mitigating the formation of neurotoxic inclusions. We review new insights on StUbL-based therapeutics and reflect perspectives of reprogramming SUMO-StUbL signaling for use in oncology and neurology.
科研通智能强力驱动
Strongly Powered by AbleSci AI